TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05307978
Drug: ALXN1910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Study: NCT05307978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
Study: NCT05958875
Drug: Second-line Antipsychotics (treatment as usual)
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
Study: NCT05159388
Drug: PRS-344/S095012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS-344/S095012 Monotherapy
Study: NCT06360640
Drug: APC148 and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05918211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05047601
Drug: Placebo for PF-07321332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05492578
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Oral Route of administration: Oral
Study: NCT06782958
Drug: 50mg FHND1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study: NCT06782958
Drug: 150 mg FHND1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study: NCT06785558
Drug: Anticholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
Study: NCT06373211
Drug: Immunoglobulins IV (CLAYRIG)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with cycles of :~- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles
Study: NCT06373211
Drug: Cyclophosphamide IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with cycles of :~- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles
Study: NCT06373211
Drug: Methylprednisolone IV
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles
Study: NCT04745949
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04745949
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05489276
Drug: TQB2825 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
Study: NCT06788236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times daily
Study: NCT05586581
Drug: SV2A PET
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
Study: NCT05586581
Drug: TSPO PET
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
Study: NCT05173818
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent
Study: NCT06465329
Drug: REGN7075
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05666310
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Study: NCT04309734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, as one or two placebo capsules, depending on the arm.
Study: NCT06384157
Drug: INDV-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
Study: NCT06457997
Drug: PHN-010
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHN-010 is an ADC
Study: NCT06788743
Drug: VA（anesthesia with sevoflurane and remifentanil）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to the VA group will receive sevoflurane combined with remifentanil for anesthesia maintenance during the surgery.
Study: NCT05231629
Drug: Dara-VRd induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
Study: NCT04396366
Drug: QBW251
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBW251, 300 mg, oral use, one capsule, twice daily.
Study: NCT04396366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, 300 mg, oral use, one capsule, twice daily.
Study: NCT06262477
Drug: BIIB800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06046443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to LB54640
Study: NCT05622708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.
Study: NCT06703073
Drug: Cohort A: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
Study: NCT06703073
Drug: Cohort B: paridiprubart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
Study: NCT06703073
Drug: Cohort B: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single IV dose of placebo on Day 1
Study: NCT06703073
Drug: Cohort C: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single IV dose of placebo on Day 1
Study: NCT04934748
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study: NCT06022861
Drug: LY01015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
Study: NCT06022861
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
Study: NCT06022861
Drug: Opdivo®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
Study: NCT06007677
Drug: STAR-0215
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-0215 will be administered as a subcutaneous injection.
Study: NCT06047080
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cyclophosphamide as part of CHP chemotherapy
Study: NCT06047080
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive IV doxorubicin
Study: NCT04805606
Drug: CKD-843-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06790095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) injection of 0.9% NaCl with the same dosing strategy as CsA: loading dose given over 2 hours, immediately followed by a continuous IV infusion for 3 days (72-hour).
Study: NCT04824092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06625489
Drug: Part A: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06625489
Drug: GSK3915393
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3915393 will be administered.
Study: NCT05889182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT06154291
Drug: XON7
Normalized name: Xon7
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
Study: NCT06784180
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mcg intrathecal fentanyl
Study: NCT04997317
Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
Study: NCT04997317
Drug: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
Study: NCT06475352
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
Study: NCT06475352
Drug: CAPOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
Study: NCT05712460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for sisunatovir
Study: NCT04742634
Drug: DEC-C
Normalized name: Dec-Chlorphen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.
Study: NCT06785727
Drug: Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).
Study: NCT06790082
Drug: [68Ga]Ga-FAPI-46 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment.
Study: NCT06499844
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Study: NCT06279000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion.
Study: NCT05108428
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
Study: NCT05108428
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
Study: NCT04938882
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT05368766
Drug: Diuretic Effect
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response to diuretic therapy
Study: NCT04536181
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks prednisolone treatment
Study: NCT04536181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks simulated tablets
Study: NCT05387278
Drug: EV-Pure™ and WJ-Pure™
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
Study: NCT05387278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryopreservation media plus standard care
Study: NCT05138653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to CVL-354
Study: NCT05093270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a tablet
Study: NCT05735327
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: As this is an observational study, no intervention will be administered.
Study: NCT05954312
Drug: VVD-130037
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05331144
Drug: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
Normalized name: Angiotensin II receptor blockers (ARBs) and calcium channel blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
Study: NCT05523089
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline for injection
Study: NCT06590012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take the placebo capsules in addition to standard treatment for a year.
Study: NCT06590012
Drug: Tertinat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take Tertinat capsules in addition to standard treatment for a year.
Study: NCT06789588
Drug: pharmacogenetic algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
Study: NCT06789588
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with AF indicated for OAC therapy guided by institutional protocol.
Study: NCT05635461
Drug: CVN424
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of either tablet or suspension formulation
Study: NCT06788171
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
Study: NCT06790693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo QD.
Study: NCT06790693
Drug: CDK4/6i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
Study: NCT05306041
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
Study: NCT06791005
Drug: Preoperative Injection of Carbon Nanoparticles
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
Study: NCT06791005
Drug: Intraoperative Injection of Carbon Nanoparticles
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
Study: NCT06523088
Drug: PN20
Normalized name: Lipram-PN20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six dose levels of PN20 will be evaluated
Study: NCT06523088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of PN20
Study: NCT06159790
Drug: GME751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
Study: NCT05316129
Drug: Follicle Stimulating Hormone Receptor T Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.